| Identification | Back Directory | [Name]
CD1530 | [CAS]
107430-66-0 | [Synonyms]
CD1530
CD1530 >=98% (HPLC)
4-(6-Hydroxy-7-tricyclo[3.3.1.13,7]dec-1-yl-2-naphthalenyl)benzoicacid
Benzoic acid, 4-(6-hydroxy-7-tricyclo[3.3.1.13,7]dec-1-yl-2-naphthalenyl)- | [Molecular Formula]
C27H26O3 | [MDL Number]
MFCD09263615 | [MOL File]
107430-66-0.mol | [Molecular Weight]
398.49 |
| Chemical Properties | Back Directory | [Boiling point ]
610.7±55.0 °C(Predicted) | [density ]
1.290±0.06 g/cm3(Predicted) | [storage temp. ]
Store at +4°C | [solubility ]
50 mM in 1 eq. NaOH: Soluble | [form ]
powder | [pka]
4.13±0.10(Predicted) | [color ]
white to beige |
| Hazard Information | Back Directory | [Uses]
CD 1530 is a retinoic acid receptor γ selective agonist. In combination with bexxarotene, they inhibit murine oral-cavity carcinogensis. It is found to inhibit heterotopic ossification and preserve tendon stem cell characteristics. It is also associated with RAR signalling in asthma. | [Biological Activity]
Potent and selective RAR γ receptor agonist (K i values are 150, 1500 and 2750 nM for RAR γ , RAR β and RAR α receptors respectively). Activates transcriptional activity (AC 50 = 1.8 nM). | [in vivo]
CD1530 (4 mg/kg; p.o.; once every other day) inhibits FOP-like heterotopic ossification in transgenic mice carrying a Cre-inducible constitutively active ALK2Q207D mutation[1].
CD1530 (2.5 mg/100 mL; p.o., in drinking water; frequency not mentioned; 15 weeks) combined with 4-nitroquinoline 1-oxide reduces the number and severity of tongue tumor lesions in mice with oral cancer[3].
CD1530 (10 μg; local injection; 3 times per week; 3 weeks) accelerates tendon healing in mice with Achilles tendon rupture, inhibits cartilage formation, reduces fibrous tissue-like scar formation, and promotes better collagen fiber alignment[4].
CD1530 (4 mg/kg, p.o.; or 1 mM, intramuscular injection; once a day; administration for 4 weeks) can inhibit muscle fat infiltration, reduce the number of intramuscular adipocytes, and reduce the expression of adipogenic marker genes in mice with rotator cuff tear[6].
| Animal Model: | C57BL/6 male mice (weight approximately 23 g, 9 weeks old) + rotator cuff tear model[6] | | Dosage: | 4 mg/kg (orally administered); 1 mM (intramuscular injection, solvent: dimethyl sulfoxide) | | Administration: | Oral administration, once a day, for 4 weeks; Intramuscular injection, once a week, for 4 weeks | | Result: | Significantly suppressed fatty infiltration in the supraspinatus muscle (p.o.).
Reduced the ratio of the fat area to the muscle cross-sectional area and the expression of adipogenic marker genes Pparg and Cebpa (p.o.).
Reduced fatty infiltration in the supraspinatus muscle (intramuscular injection).
|
| [storage]
Store at +4°C |
|
| Company Name: |
|
| Tel: |
821-50328103-801 18930552037 |
| Website: |
https://www.chemicalbook.com/ShowSupplierProductsList13285/0.htm |
| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Website: |
https://www.bocsci.com |
| Company Name: |
Energy Chemical
|
| Tel: |
021-58432009 400-005-6266 |
| Website: |
http://www.energy-chemical.com |
|